<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04843085</url>
  </required_header>
  <id_info>
    <org_study_id>69HCL20_0074</org_study_id>
    <nct_id>NCT04843085</nct_id>
  </id_info>
  <brief_title>Proteomic Characterization of Aggressive Oligodendrogliomas</brief_title>
  <acronym>PROGLIO</acronym>
  <official_title>Proteomic Characterization of Aggressive Oligodendrogliomas</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hospices Civils de Lyon</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hospices Civils de Lyon</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Oligodendrogliomas represent a distinct subgroup of adult gliomas characterized by specific&#xD;
      molecular alterations (1p/19q codeletion, mutations of IDH, TERT promoter, CIC, FUBP1). These&#xD;
      tumors account for 5 to 10% of adult gliomas and are of special relevance in the&#xD;
      neuro-oncology field because of their frequent chemosensitivity (Louis et al. 2016). The&#xD;
      genetics of oligodendrogliomas is relatively well characterized but the mechanisms of&#xD;
      oncogenesis for these tumors are poorly understood.&#xD;
&#xD;
      Although oligodendrogliomas prognosis is usually better than that of other adult glioma&#xD;
      subtypes, it remains heterogeneous and there is no effective treatment at recurrence after&#xD;
      radiotherapy and chemotherapy. Our recent work conducted within the INCa-funded national POLA&#xD;
      network has related this clinical heterogeneity to inter-tumoral heterogeneity. Based on a&#xD;
      transcriptomic analysis of a large series of oligodendroglial gliomas we identified 3&#xD;
      subgroups, the most aggressive group being characterized by aggressive clinical and molecular&#xD;
      pattern. Recent studies, however, have shown a relatively low level of concordance between&#xD;
      mRNA and protein expression, emphasizing the need to use proteomic-based approaches to better&#xD;
      understand tumor biology. Taking advantage of the POLA cohort, we propose to expand our&#xD;
      previous analysis by integrating a proteomic analysis of oligodendrogliomas.&#xD;
&#xD;
      The aim of this project is to identify drivers of oligodendroglioma subgroups, among which&#xD;
      potential druggable targets (i.e receptors, metabolism effectors). For this purpose, the&#xD;
      proteomic profiles of 90 oligodendrogliomas will be generated and integrated with&#xD;
      transcriptomic, genomic and methylation profiles in order to identify signaling pathways&#xD;
      specifically associated with each subtype, especially with the most aggressive one.&#xD;
      Associations will be explored between candidate signaling pathways expression and clinical&#xD;
      outcomes (survival, progression-free survival, objective response). The relevance of the 2&#xD;
      most promising candidate signaling pathways will be assessed in vitro and in vivo using&#xD;
      genetically relevant mouse and xenograft models.&#xD;
&#xD;
      Our project will identify targetable oncogenic pathways associated with poor prognosis that&#xD;
      could lead to new therapeutic strategies.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 30, 2020</start_date>
  <completion_date type="Anticipated">September 2023</completion_date>
  <primary_completion_date type="Anticipated">September 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>proteomic profiles</measure>
    <time_frame>Baseline (at time of diagnosis surgery)</time_frame>
    <description>Concordance of the classification of oligodendrogliomas based on their proteomic profiles with our previously identified oligodendrogliomas subgroups.</description>
  </primary_outcome>
  <number_of_groups>5</number_of_groups>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Oligodendroglioma</condition>
  <arm_group>
    <arm_group_label>O1</arm_group_label>
    <description>the more aggressive subgroup of oligodendroglioma samples of 30 patients</description>
  </arm_group>
  <arm_group>
    <arm_group_label>O2</arm_group_label>
    <description>subgroup 2 of oligodendroglioma samples of 30 patients</description>
  </arm_group>
  <arm_group>
    <arm_group_label>O3</arm_group_label>
    <description>subgroup 3 of oligodendroglioma samples of 30 patients</description>
  </arm_group>
  <arm_group>
    <arm_group_label>IDH-mutant astrocytomas</arm_group_label>
    <description>patients with IDH-mutant astrocytomas, samples of 15 patients</description>
  </arm_group>
  <arm_group>
    <arm_group_label>IDH-wildtype glioblastomas</arm_group_label>
    <description>patients with IDH-wildtype glioblastomas, samples of 15 patients</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Proteomic analysis</intervention_name>
    <description>: Proteomic analysis in the 3 subgroups of oligodendrogliomas (O1, O2 and O3) and in the comparator groups of IDH-mutant astrocytomas, IDH-wildtype glioblastomas and normal brain samples</description>
    <arm_group_label>IDH-mutant astrocytomas</arm_group_label>
    <arm_group_label>IDH-wildtype glioblastomas</arm_group_label>
    <arm_group_label>O1</arm_group_label>
    <arm_group_label>O2</arm_group_label>
    <arm_group_label>O3</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      tumoral sample and blood&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        samples of patients with oligodendrolioma, astrocytoma, glioblastoma and normal brain&#xD;
        available in the POLA network biobank or the OncoNeuroTek tumor bank (Institut du Cerveau&#xD;
        et de la Moelle Épinière)&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  - transcriptomic (microarray) data available or possible to obtain them,&#xD;
&#xD;
          -  methylation (450K) data available or possible to obtain them,&#xD;
&#xD;
          -  genomic (SNP array) data available or possible to obtain them,&#xD;
&#xD;
          -  sufficient material for proteomic analysis (frozen tumor samples)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  opposed patients&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>François DUCRAY, MD</last_name>
    <phone>04 72 35 78 06</phone>
    <email>francois.ducray@chu-lyon.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Groupement Hospitalier Est HCL</name>
      <address>
        <city>Bron</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>François Ducray, MD</last_name>
      <phone>04 72 35 78 06</phone>
      <email>francois.ducray@chu-lyon.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Institut du Cerveau et de la Moelle</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>December 2020</verification_date>
  <study_first_submitted>December 17, 2020</study_first_submitted>
  <study_first_submitted_qc>April 12, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">April 13, 2021</study_first_posted>
  <last_update_submitted>April 12, 2021</last_update_submitted>
  <last_update_submitted_qc>April 12, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 13, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Oligodendroglioma</keyword>
  <keyword>proteomic analysis</keyword>
  <keyword>POLA network</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Oligodendroglioma</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

